Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model

G. B. Vogelsang, M. C. Wells, G. W. Santos, T. L. Chen, A. D. Hess

Research output: Contribution to journalArticlepeer-review

Abstract

Thalidomide is best known as a potent teratogenic agent but has been used sporadically to treat a variety of immunologically mediated disorders. Recently, thalidomide has been shown to be an effective agent in both treating and preventing graft-v-host disease (GVHD) after bone marrow transplantation (BMT) in a rat major histocompatibility mismatched model. The present report describes our results using combination low-dose thalidomide and low-dose cyclosporine prophylaxis in this model of GVHD.

Original languageEnglish (US)
Pages (from-to)226-228
Number of pages3
JournalTransplantation proceedings
Volume20
Issue number2 SUPPL. 2
StatePublished - 1988

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Fingerprint Dive into the research topics of 'Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model'. Together they form a unique fingerprint.

Cite this